RxDoctor Payments Data

David Starks, MD

Gynecologic Oncology · Sioux Falls, SDNPI 1871751867

Payments from drug & device makers

$4,287,660in general payments, 2019–2025

Across 301 payments — averaging $14,245 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.4M
  • Takeda Pharmaceuticals U.S.A., Inc.$512K
  • Regeneron$181K
  • Clovis Oncology, Inc.$173K
  • Alkermes, Inc.$168K
  • AstraZeneca$125K
  • plus $684K from 22 others
$210in research payments, 2019–2025

Across 1 payment — averaging $209.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$210

What the payments were for

  • Consulting fees$21,99998%
  • Food & beverage$3642%
  • Education$180%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecologic oncology providers in South Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$89,145
Medicare patients
217
Services billed
580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZejulaNiraparib Tosylate18$306,780
Megestrol Acetate32$1,241
Dexamethasone26$446
Ondansetron OdtOndansetron14$202
Letrozole53$180
Gabapentin15$98
Venlafaxine Hcl ErVenlafaxine Hcl13$78
Tramadol Hcl15$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKZejula$2,009$306,78018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecologic oncology providers in South Dakotaon file to place this against a meaningful peer group, so we don't.

Other gynecologic oncology in Sioux Falls

Where these figures come from

Is this you, or does something look wrong? →